Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hideaki Shimada

Showing results (351-360 of 365) with videos related to

Pageof 37
Sort By:
International Journal of Molecular Sciences|May 11, 2024
JMJD6 Autoantibodies as a Potential Biomarker for Inflammation-Related DiseasesBo-Shi Zhang, Xiao-Meng Zhang, Masaaki Ito, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 16, 2010
Biochemical, cellular, and anti-inflammatory properties of a potent, selective, orally bioavailable benzamide inhibitor of Rho kinase activityLakshman E Rajagopalan, Michael S Davies, Larry E Kahn, et al.
Cancers|April 27, 2024
Clinical and Diagnostic Utility of Genomic Profiling for Digestive Cancers: Real-World Evidence from JapanMarin Ishikawa, Kohei Nakamura, Ryutaro Kawano, et al.
International Journal of Molecular Medicine|September 18, 2020
Association between serum anti‑ASXL2 antibody levels and acute ischemic stroke, acute myocardial infarction, diabetes mellitus, chronic kidney disease and digestive organ cancer, and their possible association with atherosclerosis and hypertensionShu-Yang Li, Yoichi Yoshida, Eiichi Kobayashi, et al.
Medicine International|July 10, 2024
Serum anti‑KIAA0513 antibody as a common biomarker for mortal atherosclerotic and cancerous diseasesTakaki Hiwasa, Yoichi Yoshida, Masaaki Kubota, et al.
Frontiers in Cardiovascular Medicine|February 27, 2023
Utility of atherosclerosis-associated serum antibodies against colony-stimulating factor 2 in predicting the onset of acute ischemic stroke and prognosis of colorectal cancerShu-Yang Li, Yoichi Yoshida, Masaaki Kubota, et al.
Ebiomedicine|November 8, 2025
Long lasting complement neutralisation by RAY121, an engineered anti-C1s antibody with C1q displacement functionAdrian W S Ho, Taku Fukuzawa, Hikaru Koga, et al.
Nature Communications|December 22, 2023
Characterizations of a neutralizing antibody broadly reactive to multiple gluten peptide:HLA-DQ2.5 complexes in the context of celiac diseaseYuu Okura, Yuri Ikawa-Teranishi, Akihiko Mizoroki, et al.
Scientific Reports|June 30, 2021
Serum anti-AP3D1 antibodies are risk factors for acute ischemic stroke related with atherosclerosisShu-Yang Li, Yoichi Yoshida, Eiichi Kobayashi, et al.
Cancer Science|September 17, 2020
Serum anti-LRPAP1 is a common biomarker for digestive organ cancers and atherosclerotic diseasesMakoto Sumazaki, Hideaki Shimada, Masaaki Ito, et al.
Pageof 37

Showing results (351-360 of 365) with videos related to

Sort By:
Pageof 37
International Journal of Molecular Sciences|May 11, 2024
JMJD6 Autoantibodies as a Potential Biomarker for Inflammation-Related DiseasesBo-Shi Zhang, Xiao-Meng Zhang, Masaaki Ito, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 16, 2010
Biochemical, cellular, and anti-inflammatory properties of a potent, selective, orally bioavailable benzamide inhibitor of Rho kinase activityLakshman E Rajagopalan, Michael S Davies, Larry E Kahn, et al.
Cancers|April 27, 2024
Clinical and Diagnostic Utility of Genomic Profiling for Digestive Cancers: Real-World Evidence from JapanMarin Ishikawa, Kohei Nakamura, Ryutaro Kawano, et al.
International Journal of Molecular Medicine|September 18, 2020
Association between serum anti‑ASXL2 antibody levels and acute ischemic stroke, acute myocardial infarction, diabetes mellitus, chronic kidney disease and digestive organ cancer, and their possible association with atherosclerosis and hypertensionShu-Yang Li, Yoichi Yoshida, Eiichi Kobayashi, et al.
Medicine International|July 10, 2024
Serum anti‑KIAA0513 antibody as a common biomarker for mortal atherosclerotic and cancerous diseasesTakaki Hiwasa, Yoichi Yoshida, Masaaki Kubota, et al.
Frontiers in Cardiovascular Medicine|February 27, 2023
Utility of atherosclerosis-associated serum antibodies against colony-stimulating factor 2 in predicting the onset of acute ischemic stroke and prognosis of colorectal cancerShu-Yang Li, Yoichi Yoshida, Masaaki Kubota, et al.
Ebiomedicine|November 8, 2025
Long lasting complement neutralisation by RAY121, an engineered anti-C1s antibody with C1q displacement functionAdrian W S Ho, Taku Fukuzawa, Hikaru Koga, et al.
Nature Communications|December 22, 2023
Characterizations of a neutralizing antibody broadly reactive to multiple gluten peptide:HLA-DQ2.5 complexes in the context of celiac diseaseYuu Okura, Yuri Ikawa-Teranishi, Akihiko Mizoroki, et al.
Scientific Reports|June 30, 2021
Serum anti-AP3D1 antibodies are risk factors for acute ischemic stroke related with atherosclerosisShu-Yang Li, Yoichi Yoshida, Eiichi Kobayashi, et al.
Cancer Science|September 17, 2020
Serum anti-LRPAP1 is a common biomarker for digestive organ cancers and atherosclerotic diseasesMakoto Sumazaki, Hideaki Shimada, Masaaki Ito, et al.
Pageof 37